Coherus BioSciences, Inc. aims to capture greater than 10% of the adalimumab market upon expected biosimilar entry in 2023, buoyed by its product, “patient-focused offering and manufacturing scale,” which it is confident “will match what payers are looking for.”
Earlier this month, the US-based player revealed a US Food and Drug Administration goal for its CHS-1420 adalimumab biosimilar candidate...






